This page is available in multiple languages
Select Language

MaaT Pharma lists on Euronext Paris

Back

  • €31.5 million raised
  • Market capitalisation of €128.4 million
  • 6th listing of a biotech on Euronext Paris in 2021
  • 175th listing on Euronext in 2021

Paris – 08 November 2021 – Euronext today congratulates MaaT Pharma, a company specialized in the research and development of microbiota biotherapies, on its listing on the regulated market of Euronext Paris (ticker code: MAAT).

Founded in 2014 and based in Lyon, MaaT Pharma is developing an innovative therapeutic approach focused on oncology through modulation of the gut microbiota. MaaT Pharma's methodology is based on its MET ("Microbiome Ecosystem Therapy") platform for the design of prospective drugs with high microbial diversity from healthy donors or produced by co-fermentation. The company is currently developing three prospective drugs, the most advanced of which is ready to enter Phase 3 clinical trials, to improve the chances of survival of patients with acute graft-versus-host disease. The IPO aims to strengthen MaaT Pharma’s development in the field of microbiota modulation in oncology, to progressively broaden its product portfolio by developing new innovative microbiota-based therapies and to build an integrated biopharmaceutical company.

MaaT Pharma was listed through the admission to trading on 8 November 2021 of the 9,514,780 shares making up its equity and of 2,333,333 new shares issued under a Global Offering[1], before the potential exercise of the over-allotment option.

The admission and issue price of MaaT Pharma shares was set at €13.5 per share. Market capitalisation was €128.4 million on the day of listing. The Initial Public Offering (IPO) raised €31.5 million altogether.

Hervé Affagard, co-founder and CEO of MaaT Pharma, said: “This IPO opens a new chapter in the history of MaaT Pharma and represents an important milestone for our sector, as it is the first listing of a company developing microbiota-based drugs in continental Europe. Our entire team would like to thank our new shareholders, both institutional and individual, as well as our historical shareholders and our ecosystem, who have chosen to contribute to our success, and whose trust honours us. The funds raised will enable us to pursue our clinical and industrial development plan and to accompany our product MaaT013 into Phase III and then towards a marketing authorisation procedure. Our ambition is to become the reference player in the world of microbiota in oncology for the benefit of millions of patients.”

MaaT Pharma

Caption: Hervé Affagard, co-founder and CEO of MaaT Pharma, rang the bell during a ceremony this morning, alongside Joël Doré, co-founder, and their associates Siân Crouzet, Savita Bernal, Isabelle Adeline, John Weinberg, Carole Schwintner and in the presence of Guillaume Morelli, Director Listing SME France at Euronext, to celebrate the IPO of the company.

About MaaT Pharma MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

 

 

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.